Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants of sensitivity to these agents, we analyzed PIK3CA-mutant cancer genomes and observed the presence of multiple PIK3C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Science
Hauptverfasser: Vasan, Neil, Razavi, Pedram, Johnson, Jared L., Shao, Hong, Shah, Hardik, Antoine, Alesia, Ladewig, Erik, Gorelick, Alexander, Lin, Ting-Yu, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Chang, Matthew T., Taylor, Barry S., Dickler, Maura N., Jhaveri, Komal, Chandarlapaty, Sarat, Rabadan, Raul, Reznik, Ed, Smith, Melissa L., Sebra, Robert, Schimmoller, Frauke, Wilson, Timothy R., Friedman, Lori S., Cantley, Lewis C., Scaltriti, Maurizio, Baselga, José
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7173400/
https://ncbi.nlm.nih.gov/pubmed/31699932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.aaw9032
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge